Aytu Biopharma Inc., a company focused on innovative treatments for central nervous system disorders, has expanded its lending agreement with Eclipse Business Capital LLC. This move extends the term loan maturity to June 2029 and increases the principal balance to $13 million, alongside a $1.5 million expansion in the revolving line of credit facility. These enhancements in financial flexibility are strategically aligned with the upcoming commercial launch of EXXUA, a first-in-class antidepressant approved by the FDA for major depressive disorder. Aytu recently secured a $16.6 million public offering to support this endeavor, positioning EXXUA as a significant growth catalyst within the $22 billion U.S. prescription MDD market.